Compare TG Therapeutics Inc (TGTX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| TGTX | VCIT | |
|---|---|---|
Market Cap | $8.26B | — |
Sector | Health | Fixed Income |
52-Week High | $59.06 | $84.82 |
52-Week Low | $26.39 | $81.45 |
Enterprise Value | $8.50B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
